List of Ongoing Diabetes-related Trials That Are Actively Recruiting Patients
|The first one is the “SUNRISE Tolerion” study||Adiposity in relation to insulin resistance
The SUNRISE study is a prospective, multi-center, double-blind, randomized, placebo-controlled trial of TOL-3021 (a plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene) in subjects aged 18.0 to <41.0 years diagnosed with Type 1 diabetes with a duration of diabetes less than 5 years. The primary outcome for the study is preservation of endogenous insulin production as measured by C-peptide during a 4 our mixed meal tolerance test (MMTT). Screening assessments will include a physical examination, retinal photograph, chemistry and hematology safety labs, urinalysis, HbA1c, presence of T1D antibodies, and an MMTT demonstrating endogenous insulin production. Qualified subjects who meet all selection criteria will be randomized in a 2:1 (active:placebo) ratio to treatment with TOL-3021 or placebo and treated with weekly IM injection, mostly at home, for 52 weeks with 2 more years of follow-up. Subjects will agree to diabetes management including wearing a study provided G6 Dexcom sensor during the study with the goal of maintaining HbA1c levels of approximately 7.0% without frequent episodes of hypoglycemia.
More details at
Study contacts Darrell Wilson, MD
Trudy Esrey, RD, CDE
|Stanford Seeks Healthy Overweight Men & Women for Diet Study||Adiposity in relation to insulin resistance
We are looking for moderately overweight (BMI 25-35) but otherwise healthy individuals between the ages of 35-65 to examine the molecular mechanisms underlying differential adipose responses to caloric excess and translation to whole body insulin resistance. Contact email@example.com if interested.
|ACTION Study||Stanford University is conducting an exciting new research study to learn how to help young people with Type 1 diabetes achieve blood glucose goals and a healthy weight at the same time. The study will test three different diets (low carbohydrate/reduced calorie, low fat/reduced calorie, and a Mediterranean diet). Participants will meet with a registered dietitian who will help them make dietary changes and monitor progress on the assigned study diet.
You may be eligible for this study if you are:
Compensation for your time and effort: You will receive money for your time and participation after each of the 4 study visits over the 10.5-month study, for a total of $700. You will also receive money when returning your stool sample at baseline and 3 months for an additional $80. It is important to know that this letter is not telling you to join this study. Your participation is voluntary. If you would like to learn more about this study, please contact us at 650-736-6660 firstname.lastname@example.org
|Medtronic 670G Hybrid Closed-Loop Trial||6 month to 1 year long trial using the 670G pump. Subjects will be randomized into using the closed-loop feature for either all 12 months or second 6 months. All subjects will be given 670G, as well as BG meter and ketone meter to use during study. Pump and meter supplies will be supplied during study. 6-9 visits to Stanford campus during that 12 months.|
|Type 1 Diabetes Clinical Trials||Attached is a list of studies we are currently recruiting for. If you have any patients who may be interested in participating, please have them send an email to email@example.com and one of our research team members will be in touch to share more information.|
|IMPACT study||Stanford Medicine and 24 hour fitness have created an exercise program for individuals with type 2 diabetes who are not using insulin.|
|Opportunity for those at risk for diabetes or have elevated cholesterol or triglycerides||Dr. Joshua Knowles and Dr. Michael Snyder are looking for volunteers ages 30-70 on a study about the relationship between cholesterol lowering medications (statins) and type 2 diabetes. The study is looking for people that may have a family history of diabetes, have pre-diabetes, have high cholesterol, or high triglycerides and are slightly to moderately overweight. In the study participants will gain information on their risk for heart disease and diabetes, and be able to meet with a certified dietitian to make lifestyle goals to help lower risks. All visits take place at the Center for Translational Research Unit at 800 Welch Rd.in Palo Alto. For more information please email: Pragya Tripathi or call 650-503-4476.|
|Liraglutide for weight loss and cardiovascular benefits||We are looking for moderately overweight but otherwise healthy pre- and type 2 diabetics between the ages of 40-69 to examine the effects of the FDA approved drug liraglutide on cardiovascular health.|
|Echo Type 1 Diabetes: Democratizing Specialty Knowledge to Improve Health Outcomes||Stanford University is launching a Project ECHOTM for Type 1 Diabetes (T1D) to support primary care providers who manage adult and/or pediatric patients with T1D who do not receive routine specialty care.|
|STRONG-D Study||The STRONG-D research study aims to help people with Type 2 Diabetes achieve a healthier lifestyle!|